

# Resource Summary Report

Generated by ASWG on Aug 2, 2026

## Thermo Fisher: TSQ Quantiva Triple-Stage Quadrupole Mass Spectrometer

RRID:SCR\_018650

Type: Tool

---

### Proper Citation

Thermo Fisher: TSQ Quantiva Triple-Stage Quadrupole Mass Spectrometer  
(RRID:SCR\_018650)

---

### Resource Information

**URL:** <http://tools.thermofisher.com/content/sfs/brochures/PS-64079-MS-TSQ-Quantiva-PS64079-EN.pdf>

**Proper Citation:** Thermo Fisher: TSQ Quantiva Triple-Stage Quadrupole Mass Spectrometer (RRID:SCR\_018650)

**Description:** Triple stage quadrupole mass spectrometer for low level quantitation and has mass range of mass per charge 10 to 1800 mass per charge. Laboratory room temperature must be maintained between 18 to 27 C and cannot change by more than 5 C.

**Resource Type:** instrument resource

**Keywords:** Liquid Chromatography Mass Spectrometer, Instrument, Equipment, USEDit, Thermo Scientific, ABRF

**Resource Name:** Thermo Fisher: TSQ Quantiva Triple-Stage Quadrupole Mass Spectrometer

**Resource ID:** SCR\_018650

**Alternate IDs:** Model\_Number\_TSQ Quantiva, SCR\_020568

**Alternate URLs:** <http://tools.thermofisher.com/content/sfs/brochures/PS-64079-MS-TSQ-Quantiva-PS64079-EN.pdf>

**Record Creation Time:** 20220129T080341+0000

**Record Last Update:** 20260801T190616+0000

---

### Ratings and Alerts

No rating or validation information has been found for Thermo Fisher: TSQ Quantiva Triple-Stage Quadrupole Mass Spectrometer.

No alerts have been found for Thermo Fisher: TSQ Quantiva Triple-Stage Quadrupole Mass Spectrometer.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [ASWG](#) .

Monteiro AC, et al. (2026) OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer. Cancer research communications, 6(1), 85.

Stromatt JC, et al. (2025) Drug-Drug Interaction Liabilities with BTK Inhibitor TL-895. Cancer research communications, 5(9), 1621.